DiObex’ candidate for the prevention of insulin-induced hypoglycemia in diabetics will be assessed with Camurus’ delivery platform.

DiObex will evaluate Camurus’ delivery technology for its diabetes-related drug. The license agreement will couple DIO-901, an extended-release formulation of low-dose glucagon for the prevention of insulin-induced hypoglycemia in diabetics, with FluidCrystal®, which has a nanoscale-matrice structure.

DiObex reports that it has successfully completed three Phase I studies using low-dose glucagon infusions in type 1 diabetic patients. The DIO-901 FluidCrystal extended-release formulation is scheduled to enter clinical trials in the second half of this year.

Terms of the agreement include a signing fee, development milestones, future royalties on product sales, and a share of any potential DiObex sublicensing revenues.

Previous articleScientists Identify SNPs Linked to Deep Vein Thrombosis
Next articleElectronic Firm Unidym Forms New Venture that Will Focus on Carbon Nanotubes in Therapeutic Applications